What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
The Trump administration is facing a legal complaint from a group of government employees affected by...
Eileen Schoch traveled to her mother's funeral in Asheville, N.C. and found the hotel room —...
The Department of Health and Human Services is freezing all childcare payments to all states, an...
US regulators on Monday gave the green light to a pill version of the blockbuster weight-loss...
